American Statistical Association
It has been shown previously that the MTD chosen by the standard method (SM) may be low, possibly leading to a non-efficacious dose. Additionally, when deviation from the original trial design occurs, the rules for determining MTD might not be applicable. We hypothesize that a retrospective analysis would suggest a MTD that is more accurate than the one obtained by the SM. In this study, we propose a method to analyze completed phase I trials and possibly amend the recommended Phase II dose, based on constrained maximum likelihood estimation (CMLE). I will present a comparison of CMLE with the retrospective Continual Reassessment Method (O’Quigley 2005) in analyzing simulated SM trials as well as existing trials from Memorial Sloan-Kettering Cancer Center. A framework for estimating confidence intervals around the toxicity probabilities at each dose level will also be presented.
|Date:||Wednesday, October 28, 2009|
|Time:||4:00 - 5:00 P.M.|
Memorial Sloan-Kettering Cancer Center
Department of Epidemiology and Biostatistics
307 East 63rd Street
(between First and Second Avenues)
3rd Floor Conference Room
New York, New York
Note: To gain access to the building, please follow the directions by the telephone in the foyer.